MiR-338-5p Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma by Inducing Apoptosis Through Targeting Survivin

Overview

Journal Sci Rep

Specialty Science

Date 2017 Sep 9

PMID 28883406

Citations 25

Authors

Misun Park

Hyeon-Joon Yoon

Moon Chul Kang

Junhye Kwon

Hae Won Lee

Affiliations

Soon will be listed here.

Abstract

Radioresistance is a challenge in the treatment of esophageal squamous cell carcinoma (ESCC). MicroRNAs (miRNAs) are known to play an important role in the functional modification of cancer cells and recent studies have reported miRNA-mediated radiotherapy resistance. However, further research is necessary to reveal the regulation mechanisms, and treatment strategies using miRNA are yet to be established for ESCC. We compared the miRNA expression profiles of ESCC parental (TE-4) and acquired radioresistance (TE-4R) cell lines using a miRNA microarray and qRT-PCR. Our data showed that miR-338-5p, one of the target miRNA biomarkers, was significantly downregulated in TE-4R. Ectopic overexpression of miR-338-5p induced apoptosis and sensitivity to radiation treatment by interfering with survivin, which is a known inhibitor of apoptosis. Overexpression of survivin reversed miR-338-5p-induced apoptosis. Tumor xenograft experiments indicated that therapeutic delivery of the miR-338-5p mimics via direct injection into tumor mass increased sensitivity to radiation therapy. In conclusion, our findings suggest that miR-338-5p is a potential radiosensitizer and may be a therapeutic biomarker for radioresistant in ESCC.

Citing Articles

MiR-338-5p, a novel metastasis-related miRNA, inhibits triple-negative breast cancer progression by targeting the ETS1/NOTCH1 axis.

Chen W, Ye Q, Wu H, Wu Z, Lan Y, Fang Z Heliyon. 2024; 10(15):e34949.

PMID: 39157351 PMC: 11327603. DOI: 10.1016/j.heliyon.2024.e34949.

Circ_0001944 depletion inhibits glycolysis and esophageal cancer progression by binding to miR-338-5p to reduce PDK1 expression.

Wang J, Yao W, Li J, Zhang Q, Wei L J Bioenerg Biomembr. 2023; 56(1):73-85.

PMID: 37999809 DOI: 10.1007/s10863-023-09988-1.

Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma.

An L, Li M, Jia Q Mol Cancer. 2023; 22(1):140.

PMID: 37598158 PMC: 10439611. DOI: 10.1186/s12943-023-01839-2.

The development of radioresistant oral squamous carcinoma cell lines and identification of radiotherapy-related biomarkers.

Huang J, Meng Q, Liu R, Li H, Li Y, Yang Z Clin Transl Oncol. 2023; 25(10):3006-3020.

PMID: 37029240 DOI: 10.1007/s12094-023-03169-7.

CircATIC inhibits esophageal carcinoma progression and promotes radiosensitivity by elevating RHCG through sponging miR-10-3p.

Zhang K, Fan R, Zhao D, Liu P, Yang Z, Liu J Thorac Cancer. 2022; 13(7):934-946.

PMID: 35307984 PMC: 8977172. DOI: 10.1111/1759-7714.14326.

References

Kim J, Kwon J, Lee H, Kang M, Yoon H, Lee S . Protein tyrosine kinase 7 plays a tumor suppressor role by inhibiting ERK and AKT phosphorylation in lung cancer. Oncol Rep. 2014; 31(6):2708-12. DOI: 10.3892/or.2014.3164. View

Chang L, Graham P, Hao J, Ni J, Bucci J, Cozzi P . Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis. 2013; 4:e875. PMC: 3920940. DOI: 10.1038/cddis.2013.407. View

Kim J, Tannock I . Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005; 5(7):516-25. DOI: 10.1038/nrc1650. View

Lin S, Gregory R . MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015; 15(6):321-33. PMC: 4859809. DOI: 10.1038/nrc3932. View

Su H, Jin X, Zhang X, Xue S, Deng X, Shen L . Identification of microRNAs involved in the radioresistance of esophageal cancer cells. Cell Biol Int. 2013; 38(3):318-25. DOI: 10.1002/cbin.10202. View

Weidhaas J, Babar I, Nallur S, Trang P, Roush S, Boehm M . MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res. 2007; 67(23):11111-6. PMC: 6070379. DOI: 10.1158/0008-5472.CAN-07-2858. View

Barker H, Paget J, Khan A, Harrington K . The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015; 15(7):409-25. PMC: 4896389. DOI: 10.1038/nrc3958. View

Wen K, Fu Z, Wu X, Feng J, Chen W, Qian J . Oct-4 is required for an antiapoptotic behavior of chemoresistant colorectal cancer cells enriched for cancer stem cells: effects associated with STAT3/Survivin. Cancer Lett. 2013; 333(1):56-65. DOI: 10.1016/j.canlet.2013.01.009. View

Shukla G, Singh J, Barik S . MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Mol Cell Pharmacol. 2012; 3(3):83-92. PMC: 3315687. View

10.

Huang S, Li X, Chen X, Che S, Chen W, Zhang X . Inhibition of microRNA-21 increases radiosensitivity of esophageal cancer cells through phosphatase and tensin homolog deleted on chromosome 10 activation. Dis Esophagus. 2012; 26(8):823-31. DOI: 10.1111/j.1442-2050.2012.01389.x. View

11.

Yang C, Peng L, Huang T, Yang G, Chu Q, Liang Y . Cancer stem-like cell characteristics induced by EB virus-encoded LMP1 contribute to radioresistance in nasopharyngeal carcinoma by suppressing the p53-mediated apoptosis pathway. Cancer Lett. 2013; 344(2):260-71. DOI: 10.1016/j.canlet.2013.11.006. View

12.

Pan X, Mou J, Liu S, Sun Z, Meng R, Zhou Z . SHP-1 overexpression increases the radioresistance of NPC cells by enhancing DSB repair, increasing S phase arrest and decreasing cell apoptosis. Oncol Rep. 2015; 33(6):2999-3005. DOI: 10.3892/or.2015.3939. View

13.

Wang P, Zhang J, Zhang L, Zhu Z, Fan J, Chen L . MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology. 2013; 145(5):1133-1143.e12. DOI: 10.1053/j.gastro.2013.07.048. View

14.

Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T . Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res. 2005; 65(11):4881-7. DOI: 10.1158/0008-5472.CAN-04-3028. View

15.

Saunders N, Simpson F, Thompson E, Hill M, Endo-Munoz L, Leggatt G . Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med. 2012; 4(8):675-84. PMC: 3494067. DOI: 10.1002/emmm.201101131. View

16.

Squatrito M, Brennan C, Helmy K, Huse J, Petrini J, Holland E . Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell. 2010; 18(6):619-29. PMC: 3818087. DOI: 10.1016/j.ccr.2010.10.034. View

17.

Rustgi A, El-Serag H . Esophageal carcinoma. N Engl J Med. 2014; 371(26):2499-509. DOI: 10.1056/NEJMra1314530. View

18.

Reichert S, Rodel C, Mirsch J, Harter P, Tomicic M, Mittelbronn M . Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma. Radiother Oncol. 2011; 101(1):51-8. DOI: 10.1016/j.radonc.2011.06.037. View

19.

Khan Z, Khan N, Tiwari R, Patro I, Prasad G, Bisen P . Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells. Radiother Oncol. 2010; 96(2):267-73. DOI: 10.1016/j.radonc.2010.06.005. View

20.

Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D . Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res. 2000; 91(11):1204-9. PMC: 5926288. DOI: 10.1111/j.1349-7006.2000.tb00906.x. View